Melasma na wan pan di prɔblɛm dɛn we kin mek pɔsin fil bad bɔt di pigmɛnt we di klinik dɛn kin trit. I kin kam bak afta laser, i kin flay wit san ɛn ɔmon, ɛn bɔku tɛm i nɔ kin ebul fɔ ansa to haydrokwinɔn nɔmɔ. Na dat mek tranexamic asid injɛkshɔn fɔ mek yu skin wayt ɛn fɔ kɔntrol melasma dɔn muf frɔm wan nich tɛknik to wan standad rikwest insay aesthetic prɔsis ɔlsay na Eshia, di Midul Is ɛn Yurop. Dis gayd de kɔba aw tranexamic acid (TXA) de wok pan pigmɛnt, wetin di klinik data we dɛn dɔn pablish rili sho, aw prɛktishɔn dɛn kin tipikul fɔ rɔn wan TXA mɛsotɛrapi protɔkɔl, ɛn wetin distribyushɔn ɛn klinik brand dɛn fɔ chɛk bifo dɛn sɔs wan TXA fɔmula.
Wetin Na Tranexamic Acid ɛn Wetin mek dɛn de yuz am pan skin?
Tranexamic acid na sεntetik dεrivεt fכ di amino asid laysin. Dɛn bin fɔs mek am as antifibrinolytic drɔg, we min se i de ridyus di blɔd bay we i de blok di kɔnvɔshɔn fɔ plasminogen to plasmin. di dεmatכlכg dεm bin intres pan am afta risechכr dεm si se fכ blכk di plasminogen–plasmin path de ridyus di ultraviolet-induced pigmentation bak.
Insay aesthetic medicine, dɛn de yuz TXA naw insay tri men we dɛn:
Tɔpikal sɛrum ɛn krim, bɔku tɛm na smɔl kɔnsɛntreshɔn
Tablɛt dɛn we dɛn kin tek bay mɔt , we dɔktɔ dɛn kin gi fɔ mek pɔsin nɔ gɛt melasma
intradεmal maykroinjεkshכn (mεsothεrapi) , usay dεn de put dilכt sכlushכn dεn dεn de put dεn wan dεm dεn wan dεm dεn de put dεm dεn wan dεm we dεn kכl di pigmεnt εria
Dis atikul de fכkus pan di tכd rod, we dεn kin sכch bכku tεm as 'tranexamic acid mesotherapy' כ 'tranexamic acid ampoule fכ skin'. Fɔ no mɔ bɔt di opshɔn dɛn we yu kin yuz fɔ mek yu gɛt braytnɛs we yu kin injɛkt, si wi gayd fɔ aw injεkshכn dεm we de mek di skin brayt de εp fכ trit di haypa pigmεntεshכn.
Aw Tranexamic Acid De Ridyus di Pigmɛnt
Melasma nɔto jɔs 'tu bɔku melanin'. I involv fɔ tɔk bitwin difrɛn kayn sɛl dɛn na di skin. Na di simpul we fɔ sho aw TXA de intarap am.
Blɔk di plasmin signal
we di skin de pan UV layt, di kεratinosayt dεm de prodyuz mכr plasminojen aktibכt. afta dat plasmin de rilis signal mכlikul dεm lεk arachidonic acid εn prostaglandins, we de push melanosayt dεm fכ prodyuz mכr melanin. TXA de blכk plasminogen aktibכshכn, so dat stimulating signal de wik na in sכs.
Target di vaskulכr kכmכpכnt
bכku tεm, di mεlaasma lεsin dεm de sho mכr sכm sכm blכd vεsul dεm pas di skin we de rawnd, εn i tan lεk se di vaskulεr growth fכktכ dεm de fכd di pigmεnt saykl. biכs TXA de akt bak pan di plasmin path we de involv insay angiojεnεsis, i kin εp wit di rεdish-brawn, vaskulכr luk fכ sכm melasma pat dεm. dis na wan rizin we mek TXA de bihayv difrεnt frכm di pure tyrosinase inhibito dεm.
Wetin mek dis impɔtant fɔ di tritmɛnt we dɛn kin pik
di tin dεm lεk glutathione, vaytam in C, kojic acid εn arbutin mכst de akt pan melanin sεntesis insεf. TXA de akt apstrim, pan di signal dεm we de trigεr am. Dat de mek i bi patna we gɛt sɛns pas fɔ bi pɔsin we go tek in ples. If yu want di ditel na di antioxidant sayd, wi atikul pan glutathione εn skin wayt injεkshכn dεm de εksplen aw glutathione de infכlכp di pigmεnt. Di ɔda pat pan dis gayd de wit TXA ɛn melasma.
Wetin di Klinik Evidɛns Sho
TXA maykroinjεkshכn dεn bin stכdi insay trial dεm we dεn kכl pipul dεn rivyu, pan כl we bכku pan dεm na sכm εn opin-lεbul. Tu stɔdi dɛn we dɛn kin tɔk bɔt bɔku tɛm de sho wan rial pikchɔ:
Lee ɛn ɔda pipul dɛn, Dɛmatɔlɔjik Sɔjri (2006). Insay wan 12 wik opin payɔl stɔdi pan 100 Korian uman dɛn we gɛt mɛlasma, dɛn injɛkt 0.05 mL TXA (4 mg/mL) insay di bɔdi na 1 cm intaval wan tɛm insay di wik. Eiti fayv pasɛnt dɛn bin dɔn di stɔdi. Di minin Melasma Eria ɛn Sivɛriti Indeks (MASI) bin fɔdɔm frɔm 13.22 na di beslayn to 7.57 na wik 12, ɛn dɛn bin diskrayb di sayd ifɛkt dɛn as smɔl.
Budamakuntla et al., Jɔnal fɔ Kutan ɛn Ɛstɛtik Sɔjri (2013). Siksti pasɛnt dɛn bin randomiz to TXA maykroinjɛkshɔn ɔ TXA we dɛn deliv wit maykronidul, wit tri mɔnt sɛshɔn. MASI impɔtant bay 35.72% na di maykroinjɛkshɔn grup ɛn 44.41% na di maykronidul grup, wit nɔ big bad bad tin we dɛn ripɔt.
Wetin dɛn stɔdi ya sho:
TXA mεsothεrapi kin prodyuz mininful rεdukshכn pan di melasma siriכs ova 8–12 wik.
Di tin dɛn we kin apin kin difrɛn. Insay di Lee stεdi, mכst pasεnshכn dεm rayt dεn improvεmεnt as 'fair' (26–50% laytin) pas komplit kliarεns.
di we aw dεn de gi di pikin impɔtant, εn if dεn kכmbayn am wit maykronidlin i kin mek di pεnεtreshכn bεtεh.
Nɔn pan dɛn tu stɔdi dɛn ya nɔ pruv se dɛn dɔn klia fɔ ɔltɛm. Melasma na wan sik we nɔ de mɛn, so di klinik dɛn fɔ prɛzɛnt TXA as kɔntrol ɛn mentenɛns tul, nɔto fɔ mɛn am.
Wan Tipik TXA Mɛsotɛrapi Prɔtokɔlɔ
Di prɔtokɔlɔ dɛn difrɛn bitwin di wan dɛn we de du di mɛrɛsin ɛn di prɔdak dɛn, ɛn ɛni tritmɛnt plan fɔ fala di instrɔkshɔn dɛn we di prɔdak gɛt fɔ yuz ɛn di lokal mɛdikal rigyuleshɔn dɛn. Di jenɛral strɔkchɔ we dɛn kin yuz na klinik dɛn kin tan lɛk dis.
Di we aw dɛn de pik di pɔsin we sik ɛn aw fɔ pripia am
Kɔnfɛm di diagnosis. Melasma, post-inflammatory hyperpigmentation εn solar lentigines de rεspכnd difrεnt wan.
Skrin fɔ si if yu nɔ gɛt ɛnitin fɔ du wit am. TXA de afɛkt di we aw di blɔd de klot, so if yu gɛt histri bɔt tromboembolism, klot disɔda, antikoagulant tɛrapi ɔ bɛlɛ, i nid fɔ mek dɔktɔ rivyu bifo di tritmɛnt.
Fɔto di eria ɔnda kɔnsistɛns layt, ɛn skor am wit MASI ɔ wan sem kayn skel fɔ ɔbjɛktiv fɔlɔp.
Klin di skin ɛn put anestetik we yu kin put pan yu bɔdi if nid de.
Teknik fɔ injɛkshɔn
dip: supεrfishal intradεmal plesmεnt, roughly 0.5–1 mm.
Spays εn volyum: sכm sכm alikכt dεm de spre ivin akɔdin to di lεsin. di protכkכl dεm we dεn pכblish yuz bכt 0.05 mL pan wan pכynt pan 1 cm intaval.
Di tin dɛn we dɛn kin yuz fɔ gi di tin dɛn: insulin sirinj, meso gɔn, ɔ maykronidling pen ɛn rɔla, i dipen pan di prɔdak dizayn ɛn di klinik we dɛn lɛk.
Sɛshɔn frɛkuɛns
Stɔdi dɛn we dɛn bin dɔn pablish bin yuz sɛshɔn dɛn we dɛn kin gɛt ɛvri wik (Lee 2006) ɔ sɛshɔn dɛn we dɛn kin gɛt ɛvri mɔnt (Budamakuntla 2013). Bɔku kɔmɛshɔnal TXA mɛsotɛrapi sɔlvishɔn dɛn kin rɛkɔmɛnd wan sɛshɔn ɛvri tu wik. Wan kɔs kin rɔn 4–8 sɛshɔn, dɔn dɛn kin gi mentenɛns tritmɛnt dɛn as nid de.
Afta dɛn dɔn kia fɔ am
Strikt brayt-spɛktrum san protɛkshɔn ɛvride. If i nɔ de, ɛni impɔtant tin we dɛn go du go dɔn.
Avɔyd ɔt, sawna ɛn strɔng aktiv fɔ 24–48 awa.
Ekspekt fɔ gɛt smɔl rɛd, pinpoint brus ɔ smɔl bɔmp we kin setul insay wan ɔ tu dez.
Kɔmbayn TXA Wit Ɔda Braytin Aktiv dɛn
di tXA in apstrim mεkanism de pe fayn wit ingridiεnt dεm we de akt fכs dכn di melanin path. Mɔdan fɔmyulashɔn dɛn kin jɔyn TXA wit:
Glutathione εn vaytam in C fכ antioksidant sכpכt εn tyrosinase inhibishכn
Intradermal TXA gɛt fayn fayn sefty rɛkɛd insay di stɔdi dɛn we dɛn dɔn pablish, bɔt rispɔnsibul yus stil dipen pan di prɔdak ɛn di pɔsin we de du am.
Steriliti εn payrojen kכntrכ l na nכn-negotiable fכ eni injεkshכn. Di prɔdak dɛn we dɛn nɔ mek fayn na big rial wɔl risk pas di aktif ingridiɛnt insɛf.
di lokal riaksh כn dεm lεk εrythema, bכn, brus εn transiεnt swel na di sayd ifekt dεm we dεn kin ripot mכst.
Dɛn kin tɔk mɔ bɔt di sistɛm risk fɔ ɔral TXA, we kin rich bɔku ay blɔd lɛvɛl. Skrin fɔ klot risk stil na gud prɔsis bifo injɛkshɔn.
Di stetmɛnt we di rigyuletɔri gɛt kin difrɛn bay di kɔntri. Insay bɔku makit dɛn, dɛn kin sɛl TXA mɛsotɛrapi sɔlvishɔn dɛn as kɔsmɛtik ɔ mɛdikal-divays prodak pas fɔ sɛl dɛn as drɔgs. Di klinik dɛn fɔ chɛk di lokal lɔ dɛn bifo dɛn yuz am.
Sos TXA Mesotherapy Solutions: Wan Chɛklist fɔ Distributɔ ɛn Klinik Brand
Diman fɔ TXA prodak dɛn strɔng na makit dɛn we gɛt ay rit fɔ melasma, we inklud Sawt Is Eshia, di Midul Is, Latin Amɛrika ɛn sɔm pat dɛn na Yurop. If yu plan fɔ import ɔ prayvet-lɛbul wan TXA fɔmula, chɛk:
Fɔmula transparency: wan ful ingridiɛnt list wit stet kɔnsɛntreshɔn, nɔto jɔs 'TXA kɔmpleks'.
Manufakchurin standad: ISO 13485 ɛn GMP-kɔmpliant prodakshɔn, wit batch rɛkɔd.
Dokumɛnt: wan sɛtifiket fɔ analisis (COA), steriliti ɛn ɛndotoksin tɛst ripɔt, ɛn stebiliti ɛn shelf-layf data fɔ ɛvri batch.
Di opshɔn dɛn fɔ pak: di vayl saiz, bɔks kwantiti ɛn lɛbl we mit yu target makit in rɛjista rikwaymɛnt dɛn.
Kastamayzεshכn: if di manifakta kin ajɔst di aktv blεnd, fכ egzampl TXA wit PDRN vεrs TXA wit glutathione, fכ yu posishכn.
AOMA de sɔpɔt distribyushɔn ɛn klinik brand dɛn wit fɔmyulashɔn, filin ɛn prayvet-lɛbul pak. Lan mɔ bɔt wi kɔstɔm mɛsotɛrapi OEM sɔlvishɔn dɛn.
FAQ we dɛn kin aks
Yu tink se tranexamic acid injection de wok fayn fɔ mek yu skin wayt?
TXA dεn bεst dεskrεb am as pigmεnt-kכntrol ingridiεnt pas 'wayt' ejen. Klinik stɔdi dɔn sho se i kin ridyus di mɛlasma siriɔs ɛn ivin ɔt tɔyn, bɔt i nɔ kin chenj pɔsin in natura skin kɔlɔ.
Ɔmɔs TXA mɛsotɛrapi sɛshɔn dɛn nid fɔ mɛlasma?
כl di kכs dεm involv 4–8 sεshכn dεm we spεshal wan to fכ wiks apat, dipכnt pan di protכkכl εn prodak. di improvεmεnt we wi kin si pan stכdi dεm we dεn pכblish bin apia arawnd 8–12 wik.
TXA mɛsotɛrapi bɛtɛ pas ɔral tranexamic asid?
Dɛn de du difrɛn tin dɛn. Oral TXA na prɛskrishɔn mɛrɛsin wit sistɛm ifɛkt ɛn nid dɔktɔ ovasayt. intradεmal TXA de gi sכm sכm lokal dכz dεrekt to di lεshכn. Wan dɔktɔ we de mɛn di bɔdi kin jɔyn dɛn tu fɔ di kes dɛm we nɔ kin gɛt di sik.
Melasma kin kam bak afta TXA tritmɛnt?
Yɛs. Melasma na krεse sik εn na UV layt, כt εn כmon dεm de trigεr am. Dɛn nid fɔ protɛkt yusɛf frɔm di san ɛvride ɛn fɔ mek yu mentenɛns wan wan tɛm fɔ mek yu gɛt di rizɔlt.
Yu tink se dɛn kin jɔyn TXA wit laser ɔ peel?
Bɔku prɛktishɔn dɛn kin yuz TXA nia jɛnɛral pil ɔ lɔw-ɛnaji layz. Di tritmɛnt dɛn fɔ gɛt spɛshal spɛshal say ɛn na kwalifay pɔshɔnal plan am fɔ avɔyd iritashɔn ɛn ribaund pigmɛnt.
Rifrens: Lee JH, Park JG, Lim SH, ɛn ɔda pipul dɛn. Lokal intradεmal maykroinjεkshכn fכ tranexamic asid fכ trit mεlasma in Eshian pasεnshכn dεm: wan prεliminεri klinik trial. Dɛrmatol Surg. 2006;32(5):626-631. Budamakuntla L, Loganathan E, Suresh D. H., ɛn ɔda pipul dɛn. Wan randomiz, opin-lɛbul, kɔmparativ stɔdi fɔ tranexamic asid maykroinjɛkshɔn ɛn tranexamic asid wit maykronidling insay pasɛnt dɛn we gɛt mɛlasma. J Kutan aesthet Surg. 2013;6(3):139–143.
Dis atikul na fɔ infɔmeshɔn bɔt pɔsin we sabi du in wok nɔmɔ ɛn nɔto dɔktɔ advays. Di tritmɛnt dɛn fɔ bi bay kwalifay prɛktishɔn dɛn we de fala di lokal rigyuleshɔn dɛn.
Dr. Emily Carter (MD, Fellow of the American Academy of Dermatology) na bɔd-sɛtifiket kɔsmɛtik sajin na Nyu Yɔk Siti wit pas 9 ia spɛshal ɛkspiriɛns pan hyaluronic acid filers, akni ska tritmɛnt, ɛn minimally invasive facial contouring. Dɛn no am mɔ fɔ in ɛkspɛriɛns pan advans injɛkshɔn tritmɛnt dɛn we de mek di akni ska dɛn layt fayn fayn wan, mek di skin wɛl, ɛn mek di skin smol bak tru di injɛkshɔn we dɛn dɔn tɔk bɔt fɔ mek di skin ripɛnt ɛn di tɛknik dɛn we dɛn de yuz fɔ mek di skin go bifo.
